Join us for Clinical Cancer Update 2026 taking place at the Everline Resort & Spa, January 23 – 25, 2026!

Meeting Overview

• Cutting-Edge Content: Our sessions will provide a comprehensive review of advances in Developmental Therapeutics, Hematologic Malignancies, Breast, Gastrointestinal, Genitourinary, Head & Neck, CNS, and Lung cancers.
• Essential Networking: Connect with esteemed peers and key industry supporters in a collaborative environment.
• Unforgettable Setting: Balance learning with free time to relax and enjoy the natural beauty of Lake Tahoe.

Learning Objectives

• Recognize and apply the latest advancements in clinical management for patients with breast, colorectal, genitourinary, and lung cancers, as well as leukemia, and lymphoma.
• Evaluate the most up-to-date chemotherapy and radiation therapy protocols for patients with breast, colorectal, genitourinary, and lung cancers; leukemia, lymphoma, and integrate these treatments into clinical practice. Focus on new developmental therapeutic options for patients.
• Identify appropriate indications for surgical intervention in breast, colorectal, genitourinary, and lung cancers, and incorporate surgical decision-making into multidisciplinary care plans.
• Gain a comprehensive understanding of recent discoveries in translational science, focusing on their relevance to breast, colorectal, genitourinary, and lung cancers; leukemia, lymphoma, and their potential clinical implications.

Agenda and Important Meeting Details

Visit the meeting registration website. 

Accreditation

REGISTER HERE

Industry Registration

What is ANCO’s Industry Registration policy?

At ANCO, we strive to foster meaningful connections and facilitate valuable interactions among participants at our meetings. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registrations for our meetings are intentionally limited. Industry Registrations are limited to a maximum of three representatives per company, from companies who are not exhibiting at the meeting, with a maximum of 15 companies.

This policy is contingent upon meeting registrations and venue capacity. If we do have additional space, we will accept more representatives.

How does the ANCO Industry Registration waitlist approval process work?

• Six weeks prior to the meeting starting, ANCO will begin approving industry registrations from the waitlist, priority will be given to industry representatives who are not exhibiting.
• Two weeks prior to ANCO meetings, ANCO will review the remaining waitlisted industry registrations. If additional space is available, ANCO may approve up to three additional industry registrations per company on the waitlist.

Exhibiting Opportunities

• Clinical Cancer Update 2026 Letter of Request
• Clinical Cancer Update 2026 Exhibitor Agreement